7,555.75

-18.75

-0.25%

51,890.00

-243.00

-0.47%

28,077.50

-50.00

-0.18%

Russell 2000 Futures

2,811.20

-6.60

-0.23%

4.8940

-0.0350

-0.71%

21.15

+1.73

+8.91%

3,926.00

-43.60

-1.10%

76,363.93

-1,673.77

-2.14%

Crude Oil Dec 26

97.42

+0.96

+1.00%

US Private Equity

10,836.30

-14.33

-0.13%

NasdaqCM - Nasdaq Real Time Price USD

OSR Health, Inc. (OSRHW)

0.0250 +0.0250 (-11.35%)

At close: August 25 at 10:56:51 AM EDT

Loading Chart for OSRHW

Chart Range Bar

Interval:

In partnership with ChartIQ

OSR Health Board Authorizes Management to Engage with Potential Acquirer of OSRK for Reverse Takeover

OSR Health Board Authorizes Management to Engage with Potential Acquirer of OSRK for Reverse Takeover

OSR Holdings Eliminates $2.02 Million Warrant Overhang with Premium-Priced Convertible Note

OSR Health Provides Shareholder Update Following Nasdaq Panel Decision

OSR Health Provides Shareholder Update Following Nasdaq Panel Decision

Emerging Growth Research Issues Company-Sponsored Research Flash Report on OSR Health, Inc.

Emerging Growth Research Issues Company-Sponsored Research Flash Report on OSR Health, Inc.

OSR Health: Preparing Our Appeal, Advancing Our Catalysts, Continuing Our Mission

OSR Health: Preparing Our Appeal, Advancing Our Catalysts, Continuing Our Mission

Sector Update: Healthcare Stocks Fall Thursday Afternoon

Sector Update: Healthcare Stocks Fall Thursday Afternoon

OSR Health Receives Nasdaq Staff Delisting Determination and Intends to Request Hearings Panel Appeal

OSR Health Receives Nasdaq Staff Delisting Determination and Intends to Request Hearings Panel Appeal

OSR Health Sees Global Shareholder Momentum at Critical Inflection Point

OSR Health Sees Global Shareholder Momentum at Critical Inflection Point

OSR Health CEO Reaffirms Confidence and Highlights Subsidiary Business Development

OSR Health CEO Reaffirms Confidence and Highlights Subsidiary Business Development

OSR Health Issues Clarification Regarding Prior Nasdaq Communication and Shareholder Loyalty CVR Program

OSR Health Issues Clarification Regarding Prior Nasdaq Communication and Shareholder Loyalty CVR Program

Vaximm AG, an OSR Company, Announces Forthcoming Publication of Cross-Indication Clinical Data for VXM01, Its VEGFR-2-Targeted Cancer Vaccine Platform

Vaximm AG, an OSR Company, Announces Forthcoming Publication of Cross-Indication Clinical Data for VXM01, Its VEGFR-2-Targeted Cancer Vaccine Platform

Mobilize your Website

View Site in Mobile | Classic

Share by: